Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism

Bone

Volumn 32, Issue 1, 2003, Pages 1-7

  Kudo, O ^a,b   Sabokbar, A ^a   Pocock, A ^a   Itonaga, I ^b   Fujikawa, Y ^b   Athanasou, N A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OITA UNIVERSITY   (Japan)

Author keywords

Bone resorption; Glycoprotein130 (gp 130); Interleukin 11 (IL 11); Interleukin 6 (IL 6); Osteoclast

Indexed keywords

CALCITONIN RECEPTOR; COLONY STIMULATING FACTOR 1; GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN ANTIBODY;

ADULT; ARTICLE; BONE REMODELING; CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; MONONUCLEAR CELL; MULTINUCLEAR CELL; NORMAL HUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN FUNCTION;

EID: 0037265995     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00915-8     Document Type: Article

References (37)

1. Al-Humidan A., Ralston S.H., Hughes D.E., Chapman K., Aarden L., Russell R.G., Gowen M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res. 6:1991;3-8.
2. Athanasou N.A., Quinn J.M. Immunophenotypic differences between osteoclasts and macrophage polykaryons immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol. 43:1990;997-1004.
3. Atkins G.J., Haynes D.R., Geary S.M., Loric M., Crotti T.N., Findlay D.M. Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone. 26:2000;653-661.
4. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclast. J Biol Chem. 275:2000;4858-4864.
5. Barton B.E. IL-6 Insight into its novel biological activities. Clin Immunology and Immunopathology. 85:1997;16-20.
6. Bataille R., Chappard D., Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 6:1992;285-295.
7. Chiba J., Rubash H., Kim K.J., Lwaki Y. The characterization of cytokines in the interface tissue obtained from cemented and cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop. 300:1994;304-312.
8. 3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res. 13:1998;393-399.
9. Devlin R.D., Bone H.G. 3rd, Roodman G.D. Interleukin-6 a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 81:1996;1893-1897.
10. Fujikawa Y., Quinn J.M.W., Sabokbar A., McGee J.O.D., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 137:1996;4058-4060.
11. Girasole G., Passeri G., Jilka R.L., Manolagas S.C. Interleukin-11 a new cytokine critical for osteoclast development. J Clin Invest. 93:1994;1516-1524.
12. Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., Roodman G.D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 97:(11):2001;3349-3353.
13. Hattersley G., Chambers T.J. Calcitonin receptors as markers for osteoclastic differentiation correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology. 125:1989;1606-1612.
14. Heymann D., Rouselle A.V. gp130 cytokine family and bone cells. Cytokine. 12:2000;1455-1468.
15. Hill, P.A., Tumber, A., Papaioannou, S., Meikle, M.C. The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology 1998;139:1564-72.
16. Hing L., Carlson L., Siebenlist U., Boyce B.F. Mechanisms by which NF-κB regulates osteoclast numbers (abstract 1172). Bone. 23:(Suppl. 1):1998;S190.
17. Hofbauer L.C., Khosla D., Dunston C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Mineral Res. 15:2000;2-12.
18. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:(3):1999;255-259.
19. Horton M.A., Lewis D., McNulty K., Pringle J.A.S., Chambers T.J. Monoclonal antibodies for osteoclastomas (giant cell bone tumors) identification of osteoclast-specific antigens. Cancer Res. 45:1985;5663-5669.
20. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., Manolagas S.C. Increased osteoclast development after oestrogen loss mediation by interleukin-6. Science. 257:1992;88-91.
21. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1254.
22. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T.J., Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 191:2000;275-286.
23. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 11:1996;88-95.
24. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
25. Lam J., Takeshita S., Baker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 106:2000;1481-1488.
26. Manolagas S.C., Bellido T., Jilka R.L. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis roles of IL-6 and gp130. Int J Immunopharmacol. 17:1995;109-116.
27. Minkin C. Bone acid phosphatase tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 34:1982;285-290.
28. Oyajobi B.O., Anderson D.M., Traianedes K., Williams P.J., Yoneda T., Mundy G.R. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61:2001;2572-2578.
29. Pietruska M., Pietruski J.K., Stokowska W., Jablonska E. Interleukin 6 and its soluble receptor in periodontitis. Arch Immunol Ther Exp. 46:1998;305-309.
30. Reddy S.V., Menaa C., Singer F.R., Demulder A., Roodman G.D. Cell biology of Paget's disease. J Bone Miner Res. 14:(Suppl. 2):1999;3-8.
31. Romas E., Udagawa N., Zhou H., Tamura T., Saito M., Taga T., Hilton D.J., Suda T., Ng K.W., Martin T.J. The role of gp130-mediated signals in osteoclast development regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 183:1996;2581-2591.
32. Roodman G.D. Interleukin-6 an osteotropic factor? J Bone Miner Res. 7:1992;475-478.
33. Roodman G.D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., Smith J.F., Singer F.R. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 89:1992;46-52.
34. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J., et al. Osteoprotegerin a novel secreted protein involved in the regulation of bone density. Cell. 80:1997;309-319.
35. Wierzbowska A., Urbanska-Rys H., Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol. 105:1999;412-419.
36. Xu J.W., Li T.F., Partsch G., Ceponis A., Santavirta S., Konttinen Y.T. Interleukin-11 (IL-11) in aseptic loosening of total hip replacement (THR). Scan J Rheumatol. 27:1998;363-367.
37. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;329-337.